Market closedNon-fractional
iTeos Therapeutics/ITOS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About iTeos Therapeutics
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.
Ticker
ITOS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Watertown, United States
Employees
157
Website
www.iteostherapeutics.com
ITOS Metrics
BasicAdvanced
$605M
Market cap
-
P/E ratio
-$3.78
EPS
1.40
Beta
-
Dividend rate
Price and volume
Market cap
$605M
Beta
1.4
52-week high
$18.75
52-week low
$8.20
Average daily volume
8.4
Financial strength
Current ratio
13.51
Management effectiveness
Return on assets (TTM)
-19.93%
Return on equity (TTM)
-22.67%
Return on investment (TTM)
-20.88%
Valuation
Price to book
1.109
Price to tangible book (TTM)
1.117
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-1,423.11%
What the Analysts think about ITOS
Analyst Ratings
Majority rating from 5 analysts.
ITOS Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$38M
25.25%
Profit margin
0.00%
NaN%
ITOS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 22
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-
-$0.96
-$0.90
-$0.85
-$1.07
Expected
$0.33
-$1.03
-$1.20
-$1.03
-$1.26
Surprise
-
-6.80%
-25.21%
-17.73%
-14.82%
ITOS News
AllArticlesVideos
iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism
Seeking Alpha·3 weeks ago
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
GlobeNewsWire·3 weeks ago
iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for iTeos Therapeutics stock?
iTeos Therapeutics (ITOS) has a market cap of $605M as of July 27, 2024.
What is the P/E ratio for iTeos Therapeutics stock?
The price to earnings (P/E) ratio for iTeos Therapeutics (ITOS) stock is 0 as of July 27, 2024.
Does iTeos Therapeutics stock pay dividends?
No, iTeos Therapeutics (ITOS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next iTeos Therapeutics dividend payment date?
iTeos Therapeutics (ITOS) stock does not pay dividends to its shareholders.
What is the beta indicator for iTeos Therapeutics?
iTeos Therapeutics (ITOS) has a beta rating of 1.4. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell iTeos Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.